Efficacy and safety of risankizumab in moderate-to-severe Crohn’s disease: a systematic review and meta-analysis
Therapeutic Advances in Gastroenterology
Published online on June 01, 2026
Abstract
Therapeutic Advances in Gastroenterology, Volume 19, January-December 2026.
Background:Crohn’s disease (CD) is a chronic inflammatory disorder with limited therapeutic options for treatment-refractory patients. This meta-analysis evaluates the efficacy and safety of risankizumab (IL-23 p19 inhibitor) in moderate-to-severe CD....
Background:Crohn’s disease (CD) is a chronic inflammatory disorder with limited therapeutic options for treatment-refractory patients. This meta-analysis evaluates the efficacy and safety of risankizumab (IL-23 p19 inhibitor) in moderate-to-severe CD....